The intravenous immunoglobulin market in the MEA is expected to grow from US$ 497.97 million in 2022 to US$ 711.99 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
Market Overview
The Middle East & Africa intravenous immunoglobulin market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia was this region's largest intravenous immunoglobulin market in 2021. The Middle East & Africa intravenous immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period; this growth can be attributed to the increasing government support for healthcare and the rising awareness regarding IgRT. The increasing prevalence of GBS and infectious diseases drives the intravenous immunoglobulin market in Saudi Arabia. According to the article, "Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19," published in the National Library of Medicine (NLM) in 2021, administration of IVIg within a specific dosage was extremely beneficial toward reducing mortality and perhaps even the length of hospitalization of patients exhibiting severe COVID-19 symptoms.
MEA Intravenous Immunoglobulin Market Segmentation
The MEA intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the MEA intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. Saudi Arabia dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 497.97 Million |
| Market Size by 2028 | US$ 711.99 Million |
| CAGR (2022 - 2028) | 6.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
The Middle East and Africa Intravenous Immunoglobulin Market is valued at US$ 497.97 Million in 2022, it is projected to reach US$ 711.99 Million by 2028.
As per our report Middle East and Africa Intravenous Immunoglobulin Market, the market size is valued at US$ 497.97 Million in 2022, projecting it to reach US$ 711.99 Million by 2028. This translates to a CAGR of approximately 6.1% during the forecast period.
The Middle East and Africa Intravenous Immunoglobulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Intravenous Immunoglobulin Market report:
The Middle East and Africa Intravenous Immunoglobulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Intravenous Immunoglobulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Intravenous Immunoglobulin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Intravenous Immunoglobulin Market
